Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of ...

Q1 2025 Earnings Call Transcript May 9, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations ...

This retrospective case series involved a review of medical records at a single tertiary care center. Charbel Issa and ...

About AAV.SPR AAV.SPR, one of Atsena's novel capsids, spreads laterally beyond the subretinal injection site to enable safe and efficient transduction of the central retina (where schisis cavities ...

Easy to administer via IVT injection, enabling broader patient access compared to more invasive subretinal injections. Manufacturable at large scales and compatible with AAV2-based processes.

following a single bilateral subretinal injection. OPGx-BEST1 is being developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies, a form of macular degeneration ...

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing ...